SGLT2 Inhibitors and Cardiovascular Outcomes

Member Cost: $0Non-member Cost: $0
Credits: 1.0 CE contact hours, 1.0 CE pharmacology hours

Course Overview

Atherosclerotic Cardiovascular Disease, Heart Failure, and SGLT2 Inhibitors

This SGLT2 inhibitor continuing education course provides timely insights into implementing evidence-based treatment strategies related to atherosclerotic cardiovascular disease, heart failure, and SGLT2 inhibitors. Darren McGuire, MD, MHSc summarizes the glycemic and non-glycemic effects of SGLT2 Inhibitors, their safety profile, and covers recent clinical outcome trials. Cindy Lamendola MSN, ANP-BC, presents case studies that highlight the role of SGLT2 inhibitors in a non-diabetic patient with atherosclerotic cardiovascular disease and heart failure.

Member Cost: $0Non-member Cost: $0
Credits: 1.0 CE contact hours, 1.0 CE pharmacology hours


Learning Objectives

Upon completion of this course, participants will be able to:

  1. Describe the clinical efficacy and safety profile of SGLT2 inhibitors.
  2. Interpret CV and heart failure outcomes associated with SGLT2 inhibitors.
  3. Demonstrate prudent use of SGLT2 inhibitors in clinical practice.


  • Darren McGuire, MD, MHSc
  • Cindy Lamendola MSN, ANP-BC

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of PCNA. PCNA is accredited by AANP as an approved provider of nurse practitioner continuing education. Provider number: 030602.